| Source: |
| Type: |
| Toxicity |
| 1341- | 3BP, | The HK2 Dependent “Warburg Effect” and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate |
| - | Review, | NA, | NA |
| 5281- | 3BP, | A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside |
| - | Case Report, | Var, | NA |
| 5278- | 3BP, | The effect of 3-bromopyruvate on human colorectal cancer cells is dependent on glucose concentration but not hexokinase II expression |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | Caco-2 | - | in-vitro, | CRC, | SW48 |
| 5274- | 3BP, | ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 |
| - | in-vitro, | PC, | NA |
| 5257- | 3BP, | Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment |
| - | Review, | Var, | NA |
| 5259- | 3BP, | Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP |
| - | in-vivo, | HCC, | NA |
| 5260- | 3BP, | Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer |
| - | in-vivo, | PC, | NA |
| 5269- | 3BP, | The anti-metabolite KAT/3BP has in vitro and in vivo anti-tumor activity in lymphoma models. |
| - | in-vitro, | HCC, | NA |
| 5264- | 3BP, | Candidate cancer drug suspected after death of three patients at an alternative medicine clinic |
| - | Review, | Var, | NA |
| 5302- | 5-HTP, | Hippocampal ischaemia from accidental 5-Hydroxytryptophan (5-HTP) overdose case report |
| - | Case Report, | Nor, | NA |
| 5310- | 5-HTP, | 5-Hydroxytryptophan toxicity successfully treated by haemodialysis in a dog |
| - | Case Report, | Nor, | NA |
| 5298- | 5-HTP, | Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa |
| - | Human, | AD, | NA |
| 5295- | 5-HTP, | Safety of 5-hydroxy-L-tryptophan |
| - | in-vivo, | Nor, | NA |
| 5294- | 5-HTP, | Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan |
| - | in-vivo, | Nor, | NA |
| 5289- | 5-HTP, | 5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology |
| - | Review, | AD, | NA | - | Review, | Arthritis, | NA |
| 5301- | 5-HTP, | Eosinophilia-myalgia syndrome presenting with overlapping features of eosinophilic fasciitis and sarcoidal granulomas |
| - | Case Report, | NA, | NA |
| 5300- | 5-HTP, | The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice |
| - | Review, | Nor, | NA |
| 5299- | 5-HTP, | Serotonin Syndrome from 5-Hydroxytryptophan Supplement Ingestion in a 9-Month-Old Labrador Retriever |
| - | Case Report, | AD, | NA |
| 5307- | 5-HTP, | 5-Hydroxytryptophan toxicosis in dogs: 1989-1999 |
| - | Case Report, | Nor, | NA |
| 5305- | 5-HTP, | An Investigation of the Cause of the Eosinophilia–Myalgia Syndrome Associated with Tryptophan Use |
| - | Review, | Nor, | NA |
| 5466- | AF, | Auranofin Inhibition of Thioredoxin Reductase in a Preclinical Model of Small Cell Lung Cancer |
| - | in-vivo, | Lung, | NA |
| 5461- | AF, | Dual inhibition of thioredoxin reductase and proteasome is required for auranofin-induced paraptosis in breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 5458- | AF, | Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer |
| - | in-vitro, | NSCLC, | NA |
| 5456- | AF, | Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent |
| - | Trial, | Nor, | NA |
| 5468- | AF, | The gold complex auranofin: new perspectives for cancer therapy |
| - | Review, | Var, | NA |
| 5443- | AG, | Pharmacokinetics and tolerance of toal astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers |
| - | Human, | Nor, | NA |
| 5436- | AG, | Therapeutic Effect of Astragalus Polysaccharides on Hepatocellular Carcinoma H22-Bearing Mice |
| - | in-vivo, | HCC, | NA |
| 5976- | AgNPs, | Review on Harnessing Silver Nanoparticles for Therapeutic Innovations: A Comprehensive Review on Medical Applications, Safety, and Future Directions |
| - | Review, | Vit, | NA |
| 4402- | AgNPs, | Enhancement of Triple-Negative Breast Cancer-Specific Induction of Cell Death by Silver Nanoparticles by Combined Treatment with Proteotoxic Stress Response Inhibitors |
| - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 4361- | AgNPs, | GoldNP, | Biocompatible silver, gold and silver/gold alloy nanoparticles for enhanced cancer therapy: in vitro and in vivo perspectives |
| - | in-vivo, | Liver, | HepG2 |
| 4360- | AgNPs, | Silver Nanoparticles as Real Topical Bullets for Wound Healing |
| - | Study, | Nor, | NA |
| 4359- | AgNPs, | Antimicrobial Silver Nanoparticles for Wound Healing Application: Progress and Future Trends |
| - | NA, | Wounds, | NA |
| 4428- | AgNPs, | p38 MAPK Activation, DNA Damage, Cell Cycle Arrest and Apoptosis As Mechanisms of Toxicity of Silver Nanoparticles in Jurkat T Cells |
| - | in-vitro, | AML, | Jurkat |
| 4429- | AgNPs, | Comparative proteomic analysis reveals the different hepatotoxic mechanisms of human hepatocytes exposed to silver nanoparticles |
| - | in-vitro, | Liver, | HepG2 |
| 4430- | AgNPs, | Evaluation of the Genotoxic and Oxidative Damage Potential of Silver Nanoparticles in Human NCM460 and HCT116 Cells |
| - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Nor, | NCM460 |
| 4363- | AgNPs, | Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma |
| - | in-vivo, | fibroS, | NA |
| - | vitro+vivo, | Nor, | NA |
| 4447- | AgNPs, | Anti-inflammatory action of silver nanoparticles in vivo: systematic review and meta-analysis |
| - | Review, | Nor, | NA |
| 4365- | AgNPs, | Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview |
| - | Review, | Var, | NA |
| 4561- | AgNPs, | VitC, | Cellular Effects Nanosilver on Cancer and Non-cancer Cells: Potential Environmental and Human Health Impacts |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | HEK293 |
| 4556- | AgNPs, | Biofilm Impeding AgNPs Target Skin Carcinoma by Inducing Mitochondrial Membrane Depolarization Mediated through ROS Production |
| - | in-vitro, | Melanoma, | A431 |
| 4553- | AgNPs, | Cytotoxicity induced by engineered silver nanocrystallites is dependent on surface coatings and cell types |
| - | in-vitro, | Nor, | RAW264.7 |
| 4600- | AgNPs, | Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model |
| - | in-vivo, | Nor, | NA |
| 4598- | AgNPs, | In vivo human time-exposure study of orally dosed commercial silver nanoparticles |
| - | in-vivo, | Nor, | NA |
| 4581- | AgNPs, | Antimicrobial, anticoagulant and antiplatelet activities of green synthesized silver nanoparticles using Selaginella (Sanjeevini) plant extract |
| 4577- | AgNPs, | Characterization of Antiplatelet Properties of Silver Nanoparticles |
| - | vitro+vivo, | Stroke, | NA |
| 4573- | AgNPs, | Bioactive silver nanoparticles derived from Carica papaya floral extract and its dual-functioning biomedical application |
| - | in-vitro, | Var, | MCF-7 | - | NA, | NA, | HEK293 |
| 5144- | AgNPs, | Differential effects of silver nanoparticles on DNA damage and DNA repair gene expression in Ogg1-deficient and wild type mice |
| - | in-vivo, | Nor, | NA |
| 375- | AgNPs, | ALA, | Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vivo, | NA, | NA |
| 305- | AgNPs, | Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer |
| - | Case Report, | HNSCC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1025 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid